---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-026592"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:49:56.053422+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Natera Q4 revenue $173M (+54% YoY); net loss widens to $140.6M; FY 2022 guidance $770-790M

## Summary
- Q4 2021 revenue $173.0M (+53.9% YoY); full year 2021 revenue $625.5M (+60% YoY), exceeding prior guidance.
- Q4 net loss $140.6M ($1.48/share) vs $76.4M loss ($0.89/share) in Q4 2020; FY 2021 net loss $471.7M ($5.21/share).
- Processed ~438,800 tests in Q4 (+48.7% YoY); full year ~1,570,000 tests processed.
- FY 2022 guidance: revenue $770M-$790M; gross margin ~46%-48%; SG&A $560M-$590M; R&D $340M-$360M; net cash consumption $370M-$400M.
- Received CMS coverage for Signatera pan-cancer monitoring; presented positive data from Trifecta and CIRCULATE-Japan studies.

## SEC filing metadata
- accession: 0001104659-22-026592
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465922026592/0001104659-22-026592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465922026592/tm227574d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-026592
- JSON: https://secwatch.observer/filing/0001104659-22-026592.json
- Plain text: https://secwatch.observer/filing/0001104659-22-026592.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.